<DOC>
	<DOCNO>NCT00754767</DOCNO>
	<brief_summary>RATIONALE : L-carnitine L-tartrate may prevent peripheral neuropathy cause chemotherapy . PURPOSE : This randomized clinical trial study well L-carnitine L-tartrate work prevent peripheral neuropathy cause chemotherapy woman metastatic breast cancer .</brief_summary>
	<brief_title>L-Carnitine L-Tartrate Preventing Peripheral Neuropathy Caused By Chemotherapy Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate tolerability usefulness dietary supplement , L-carnitine L-tartrate , prevention chemotherapy-induced peripheral neuropathy woman metastatic breast cancer . OUTLINE : Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral L-carnitine L-tartrate twice daily begin day 2 first course chemotherapy continue completion 4 course chemotherapy . - Arm II : Patients receive oral placebo twice daily begin day 2 first course chemotherapy continue completion 4 course chemotherapy . Patients complete questionnaire periodically assess neuropathy , pain , fatigue , sleep , activity daily live . After completion study treatment , patient follow 4 week every 3 month thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Metastatic disease Scheduled receive ≥ 1 follow chemotherapy drug : Paclitaxel Docetaxel Capecitabine Gemcitabine hydrochloride Concurrent enrollment University Minnesota study `` Population Pharmacokinetics Pharmacogenetics Gemcitabine Adult Patients Solid Tumors '' ( Human Subjects Code 0508M72989 ) require Albuminbound paclitaxel ( Abraxane ) Doxorubicin hydrochloride PATIENT CHARACTERISTICS : Life expectancy ≥ 6 month Serum creatinine &lt; 2.0 mg/dL Not pregnant nursing Fertile patient must use effective contraception No history seizures No uncontrolled hypertension No history stroke No malabsorption syndrome No cognitive impairment No history psychiatric disability affect informed consent compliance drug intake Able take oral medication Able complete questionnaire ( ) alone assistance PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent warfarin No concurrent radiotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>